A PHASE 1 OPEN-LABEL CLINICAL TRIAL TO ESTABLISH THE SAFETY, TOLERABILITY, DOSE RANGE, AND PHARMACOKINETIC PROFILE OF INTRAVITREAL INJECTION OF TH103 IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (THEIA1000)
Research Grant
Administered By
Ophthalmology
Awarded By
Kalaris Therapeutics, Inc.
Start Date
June 10, 2024
End Date
June 30, 2026
Administered By
Ophthalmology
Awarded By
Kalaris Therapeutics, Inc.
Start Date
June 10, 2024
End Date
June 30, 2026